Comprehensive Care – difference and common aspects of acute treatment and chronic care


From Prof. Dr. Ley Sander, London, UK


Berlin (20. September 2008) – Epilepsy is the most common serious neurological disorder with a lifetime prevalence of between two and five percent. Many of those developing epilepsy do so at a young age.  The prevalence of active epilepsy (ie people with ongoing seizures) is up to one percent of the general population. For many people who develop epilepsy, the condition is short lived, but in about one fifth of those who develop epilepsy the condition becomes chronic with little prospect for full seizure remission.


Having recurrent epileptic seizures has implications in a number of life domains and these include education, employment, relationships, and leisure. The propensity to recurrent epileptic seizures may curtail someone’s independence and severely impact on quality of life. An acute epilepsy care model may be adequate in treating seizures acutely and may avoid direct medical complications but usually disregards these important aspects of a person’s life. On the other hand, a comprehensive care model provides a holistic approach to the person with the condition.


The delivery of comprehensive care involves a multidisciplinary team whilst acute care is usually based on physician only health delivery, focusing mainly on seizure control. This acute approach may well be adequate for those who have a short lived condition. Comprehensive care often involves voluntary agencies and support groups in addition to the multidisciplinary team. The team delivering comprehensive care usually consists of physicians of various disciplines (neurologists, paediatricians, neurophysiologists, neurosurgeons, psychiatrists, and learning disability specialists), epilepsy specialist nurses, therapists (speech, physio, occupational), social workers as well as counsellors. The team has access to full diagnostic facilities and well as to neurosurgical services. Comprehensive care is proactive and will engage in careful planning of a person’s management path. This is in contrast to acute care which is usually reactive and ad hoc. Comprehensive care is better placed to consider, for instance, the feasibility of epilepsy surgery in an individual person and to plan for it. It may also plan ahead for changes in life status of a person (for example, planned pregnancy).  People with well-controlled epilepsy may wish to taper or stop anti-epileptic drug therapy, and this should be the province of comprehensive care. This comprehensive care usually provides full information to the people it serves and will have an open access policy. Comprehensive epilepsy care also involves planned shared care with the primary care provider. There will be a shared-care protocol as well as guidelines for urgent access to the comprehensive care centre.


Despite the intuitive feeling that comprehensive care is better than acute care for people with epilepsy, there is no clear evidence to confirm this. Nevertheless, given the opportunity most people with epilepsy would prefer a comprehensive health delivery approach over the option of ad hoc management. A comprehensive approach usually provides continuity of care which is one of the features that people with epilepsy most appreciate in their assessment of health care delivery.


This presentation will discuss these issues, comparing and contrasting the acute care delivery approach to a full comprehensive care model for people with epilepsy.




Slide 1: Scope of epilepsy.





Slide 2: Compehensive care.





Slide 3: Comprehensive epilepsy care.





Slide 4: Comprehensive care better?





Source: 8th European Congress on Epiteptology, Satellite Symposium: “Comprehensive Care of Epilepsy in Europe”, Berlin, 20. September 2008 (Medizin und PR Kommunikation).


IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…


Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln


Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT


Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn


Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen


Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?


Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…